Inhibition of mTOR/S6K1/4E-BP1 Signaling by Nutraceutical SIRT1 Modulators

Nutrition and Cancer

Volumn 70, Issue 3, 2018, Pages 490-501

  Bianchi, Sara ^a   Giovannini, Luca ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BERBERINE; FERULIC ACID; INITIATION FACTOR 4E BINDING PROTEIN 1; NUTRACEUTICAL; QUERCETIN; SIRTUIN 1; TYROSOL; 4-HYDROXYPHENYLETHANOL; COUMARIC ACID; EIF4EBP1 PROTEIN, HUMAN; MTOR PROTEIN, HUMAN; PHENETHYL ALCOHOL; PHOSPHOPROTEIN; RIBOSOMAL PROTEIN S6 KINASE, 70KD, POLYPEPTIDE 1; S6 KINASE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SIRT1 PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

AMPK SIGNALING; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HUMAN; MTOR SIGNALING; PROTEIN PHOSPHORYLATION; SINGLE DRUG DOSE; ANALOGS AND DERIVATIVES; DIETARY SUPPLEMENT; DRUG POTENTIATION; HELA CELL LINE; METABOLISM; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; BERBERINE; COUMARIC ACIDS; DIETARY SUPPLEMENTS; DRUG SYNERGISM; HELA CELLS; HUMANS; PHENYLETHYL ALCOHOL; PHOSPHOPROTEINS; PHOSPHORYLATION; QUERCETIN; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; SIRTUIN 1; TOR SERINE-THREONINE KINASES;

EID: 85044060338     PISSN: 01635581     EISSN: 15327914     Source Type: Journal    
DOI: 10.1080/01635581.2018.1446093     Document Type: Article

References (90)

1. Zarogoulidis P, Lampaki S, Turner JF, Huang H, Kakolyris S, Syrigos K, et al.: mTOR pathway: A current, up-to-date mini-review (Review). Oncol Lett 8, 2367–2370, 2014.
2. Baretić D, and Williams RL, : The structural basis for mTOR function. Semin Cell Dev Biol 36, 91–101, 2014. doi:10.1016/j.semcdb.2014.09.024.
3. Dazert E, and Hall MN, : mTOR signaling in disease. Curr Opin Cell Biol 23, 744–55, 2011. Review doi:10.1016/j.ceb.2011.09.003.
4. Zoncu R, Efeyan A, and Sabatini DM, : mTOR: From growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12, 21–35, 2011. Review doi:10.1038/nrm3025.
5. Tsang CK, Qi H, Liu LF, and Zheng XF, : Targeting mammalian target of rapamycin (mTOR) for health and diseases. Drug Discov Today 12, 112–24, 2007. Review.
6. Switon K, Kotulska K, Janusz-Kaminska A, Zmorzynska J, and Jaworski J, : Molecular neurobiology of mTOR. Neuroscience 341, 112–153, 2017. Review. doi:10.1016/j.neuroscience.2016.11.017.
7. Guertin DA, and Sabatini DM, : Defining the role of mTOR in cancer. Cancer Cell 12, 9–22, 2007.
8. Peterson TR, Laplante M, Thoreen CC, Sancak Y, Kang SA, Kuehl WM, et al.: DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 137, 873–86, 2009. doi:10.1016/j.cell.2009.03.046.
9. Laplante M, and Sabatini DM, : mTOR signaling at a glance. J Cell Sci 122, 3589–94, 2009. Review. doi:10.1242/jcs.051011.
10. Oh WJ, and Jacinto E, : mTOR complex 2 signaling and functions. Cell Cycle 10, 2305–16, 2011.
11. Fingar DC, Salama S, Tsou C, Harlow E, and Blenis J, : Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev 16, 1472–87, 2002.
12. Nojima H, Tokunaga C, Eguchi S, Oshiro N, Hidayat S, Yoshino K, et al.: The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif. J Biol Chem 278, 15461–4, 2003.
13. Fenton TR, and Gout IT, : Functions and regulation of the 70kDa ribosomal S6 kinases. Int J Biochem Cell Biol 43, 47–59, 2011. Review. doi:10.1016/j.biocel.2010.09.018.
14. Dufner A, and Thomas G, : Ribosomal S6 kinase signaling and the control of translation. Experimental Cell Research 253, 100–109, 1999.
15. Avruch J, Belham C, Weng Q, Hara K, and Yonezawa K, : The p70 S6 kinase integrates nutrient and growth signals to control translational capacity. ProgMolSubcell Biol 26, 115–54, 2001. Review.
16. Keshwani MM, von Daake S, Newton AC, Harris TK, and Taylor SS, : Hydrophobic motif phosphorylation is not required for activation loop phosphorylation of p70 ribosomal protein S6 kinase 1 (S6K1). J Biol Chem 286, 23552–8, 2011. doi:10.1074/jbc.M111.258004.
17. Selman C, Tullet JM, Wieser D, Irvine E, Lingard SJ, Choudhury AI, et al.: Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. Science 326, 140–4, 2009. doi:10.1126/science.1177221.
18. Ming XF, Montani JP, and Yang Z, : Perspectives of targeting mTORC1–S6K1 in cardiovascular aging Frontiers in physiology. 5, 1–11, 2012. Review doi:10.3389/fphys.2012.00005.
19. Dann SG, Selvaraj A, and Thomas G, : mTORComplex1-S6K1 signaling: At the crossroads of obesity, diabetes and cancer. TrendsMol 13, 252–259, 2007.
20. Alain T, Morita M, Fonseca BD, Yanagiya A, Siddiqui N, Bhat M, et al.: eIF4E/4E-BP Ratio Predicts the Efficacy of mTOR Targeted Therapies. Cancer Research 72, 6468–6476, 2012. doi:10.1158/0008-5472.CAN-12-2395.
21. Gingras AC, Kennedy SG, O'Leary MA, Sonenberg N, and Hay N, : 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. Genes Dev 12, 502–13, 1998.
22. Schalm SS, Fingar DC, Sabatini DM, and Blenis J, : TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and function. Curr. Biol 13, 797–806, 2003.
23. Zhou H, and Huang S, : mTOR signaling in cancer cell motility and tumor metastasis. Crit Rev Eukaryot Gene Expr 20, 1–16, 2010. Review.
24. Beauchamp EM, and Platanias LC, : The evolution of the TOR pathway and its role in cancer. Oncogene 32, 3923–32, 2013. doi:10.1038/onc.2012.567. Review.
25. Yamnik RL, Digilova A, Davis DC, Brodt ZN, Murphy CJ, and Holz MK, : S6 kinase 1 regulates estrogen receptor alpha in control of breast cancer cell proliferation. J Biol Chem 284, 6361–9, 2009. doi:10.1074/jbc.M807532200.
26. Ismail HM, : Overexpression of s6 kinase 1 in brain tumours is associated with induction of hypoxia-responsive genes and predicts patients' survival. J Oncol 2012, 416927, 2012. doi:10.1155/2012/416927.
27. Rojo F, Najera L, Lirola J, Jiménez J, Guzmán M, Sabadell MD, et al.: 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis. Clin Cancer Res 13, 81–9, 2007.
28. She QB, Halilovic E, Ye Q, Zhen W, Shirasawa S, Sasazuki T, et al.: 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell 18, 39–51, 2010. doi:10.1016/j.ccr.2010.05.023.
29. Ruggero D, Montanaro L, Ma L, Xu W, Londei P, et al.: The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med 10, 484–6, 2004.
30. Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, et al.: Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428, 332–7, 2004.
31. Hay N, and Sonenberg N, : Upstream and downstream of mTOR. Genes Dev 18, 1926–45, 2004. Review.
32. Neuhaus P, Klupp J, and Langrehr JM, : mTOR inhibitors: An overview. Liver Transpl 7, 473–84, 2001.
33. Guertin DA, and Sabatini DM, : The pharmacology of mTOR inhibition. Sci Signaling 2, pe24, 2009. doi:10.1126/scisignal.267pe24.
34. Tan HK, Moad AI, and Tan ML, : The mTORsignalling pathway in cancer and the potential mTOR inhibitory activities of natural phytochemicals. Asian Pac J Cancer Prev 15, 6463–75, 2014.
35. Garami A, Zwartkruis FJ, Nobukuni T, Joaquin M, Roccio M, Stocker H, et al.: Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol Cell 11, 1457–66, 2003.
36. Vilar E, Perez-Garcia J, and Tabernero J, : Pushing the envelope in the mTOR pathway: The second generation of inhibitors. Mol Cancer Ther 10, 395–403, 2011. Review doi:10.1158/1535-7163.MCT-10-0905.
37. Naiman S, and Cohen HY, : The contentious history of sirtuin debates. Rambam Maimonides Med Journal 3, e0022, 2012. doi:10.5041/RMMJ.10093.
38. Houtkooper RH, Pirinen E, and Auwerx J, : Sirtuins as regulators of metabolism and healthspan. Nat Rev Mol Cell Biol 13, 225–38, 2012. doi:10.1038/nrm3293.
39. Chang HC, and Guarente L, : SIRT1 and other sirtuins in metabolism. Trends EndocrinolMetab 25, 138–45, 2014. doi:10.1016/j.tem.2013.12.001.
40. Davenport AM, Huber FM, and Hoelz A, : Structural and functional analysis of human SIRT1. J Mol Biol 426, 526–41, 2014. doi:10.1016/j.jmb.2013.10.009.
41. Yakamoto H, Schoonjans L, and Auwerx J, : Sirtuin functions in health and disease. MolEndocrinol 21, 1745–55, 2007.
42. Kwon HS, and Ott M, : The ups and downs of SIRT1. Trends Biochem Sci 33, 517–25, 2008. doi:10.1016/j.tibs.2008.08.001.
43. Cantó C, Gerhart-Hines Z, Feige JN, Lagouge M, Noriega L, et al.: AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature 458, 1050–60, 2009. doi:10.1038/nature07813.
44. Narala SR, Allsopp RC, Wells TB, Zhang G, Prasad P, Coussens MJ, et al.: SIRT1 acts as a nutrient-sensitive growth suppressor and its loss is associated with increased AMPK and telomerase activity. MolBiol Cell 19, 1210–9, 2008. doi:10.1091/mbc.E07-09-0965.
45. Lan F, Cacicedo JM, Ruderman N, and Ido Y, : SIRT1 modulation of the acetylation status, cytosolic localization, and activity of LKB1. Possible role in AMP-activated protein kinase activation. J Biol Chem 283, 27628–35, 2008. doi:10.1074/jbc.M805711200.
46. Hardie DG, : AMPK: Positive and negative regulation, and its role in whole-body energy homeostasis. CurrOpin Cell Biol 33, 1–7, 2015. doi:10.1016/j.ceb.2014.09.004.
47. Shirwany NA, and Zou MH, : AMPK: A cellular metabolic and redox sensor. A minireview. Front Biosci 19, 447–74, 2014. Review.
48. Sun Y, Li J, Xiao N, Wang M, Kou J, Qi L, et al.: Pharmacological activation of AMPK ameliorates perivascular adipose/endothelial dysfunction in a manner interdependent on AMPK and SIRT1. Pharmacol Res 89, 19–28, 2014. doi:10.1016/j.phrs.2014.07.006.
49. Jeong HW, Cho SY, Kim SY, Shin ES, Kim JM, et al.: Chitooligosaccharide induces mitochondrial biogenesis and increases exercise endurance through the activation of Sirt1 and AMPK in rats. PLoS One 7, 2012. doi:10.1371/journal.pone.0040073.
50. Zhuo L, Fu B, Bai X, Zhang B, Wu L, et al.: NAD blocks high glucose induced mesangial hypertrophy via activation of the sirtuins-AMPK-mTOR pathway. Cell PhysiolBiochem 27, 681–90, 2011. doi:10.1159/000330077.
51. Tillu DV, Melemedjian OK, Asiedu MN, Qu N, De Felice M, Dussor G, et al.: Resveratrol engages AMPK to attenuate ERK and mTOR signaling in sensory neurons and inhibits incision-induced acute and chronic pain. Mol Pain 8, 5, 2012. doi:10.1186/1744-8069-8-5.
52. Kimura N, Tokunaga C, Dalal S, Richardson C, Yoshino K, et al.: A possible linkage between AMP-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) signaling pathway. Genes Cells 8, 65–79, 2003.
53. Ghosh HS, McBurney M, and Robbins PD, : SIRT1 negatively regulates the mammalian target of rapamycin. PLoS One 5, e9199, 2010. doi:10.1371/journal.pone.0009199.
54. Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, et al.: AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 30, 214–26, 2008. doi:10.1016/j.molcel.2008.03.003.
55. Kelly G, : A review of the Sirtuin system, its Clinical Implications, and the Potential Role of Dietary Activators: Part 1. Altern Med Rev 15, 245–263, 2010.
56. Kucińska M, Piotrowska H, and Murias M, : Sirtuins–modulation of their activity as a novel therapeutic target. Pol MerkurLekarski 28, 231–5, 2010.
57. Sauve AA, Wolberger C, Schramm VL, and Boeke JD, : The biochemistry of sirtuins. Annu Rev Biochem 435–465, 2006.
58. Giovannini L, and Bianchi S, : Role of nutraceutical SIRT1 modulators in AMPK and mTOR pathway: Evidence of a synergistic effect. Nutrition 34, 82–96, 2017. doi:10.1016/j.nut.2016.09.008.
59. Wang LM, Wang YJ, Cui M, Luo WJ, Wang XJ, et al.: A dietary polyphenol resveratrol acts to provide neuroprotection in recurrent stroke models by regulating AMPK and SIRT1 signaling, thereby reducing energy requirements during ischemia. Eur J Neurosci 37(10), 1669–81, 2013 May. doi:10.1111/ejn.12162.
60. Ganesan R, Hos NJ, Gutierrez S, Fischer J, Stepek JM, et al.: Salmonella Typhimurium disrupts Sirt1/AMPK checkpoint control of mTOR to impair autophagy. PLoSPathog 13, e1006227, 2017. doi:10.1371/journal.ppat.1006227.
61. Ruderman NB, Xu XJ, Nelson L, Cacicedo JM, Saha AK, et al.: AMPK and SIRT1: A long-standing partnership? Am J PhysiolEndocrinolMetab 298, E751–60, 2010. Review doi:10.1152/ajpendo.00745.2009.
62. Wang S, Moustaid-Moussa N, Chen L, Mo H, Shastri A, et al.: Novel insights of dietary polyphenols and obesity. J NutrBiochem 25, 1–18, 2014. doi:10.1016/j.jnutbio.2013.09.001.
63. Chi L, Peng L, Pan N, Hu X, and Zhang Y, : The anti-atherogenic effects of berberine on foam cell formation are mediated through the upregulation of sirtuin 1. Int J Mol Med 34, 1087–93, 2014. doi:10.3892/ijmm.2014.1868.
64. Zhu X, Guo X, Mao G, Gao Z, Wang H, et al.: Hepatoprotection of berberine against hydrogen peroxide-induced apoptosis by upregulation of Sirtuin 1. Phytother Res 27, 417–21, 2013. doi:10.1002/ptr.4728.
65. Gomes AP, Duarte FV, Nunes P, Hubbard BP, Teodoro JS, et al.: Berberine protects against high fat diet-induced dysfunction in muscle mitochondria by inducing SIRT1-dependent mitochondrial biogenesis. BiochimBiophysActa 1822, 185–95, 2012. doi:10.1016/j.bbadis.2011.10.008.
66. Samuel SM, Thirunavukkarasu M, Penumathsa SV, Paul D, and Maulik N, : Akt/FOXO3a/SIRT1-mediated cardioprotection by n-tyrosol against ischemic stress in rat in vivo model of myocardial infarction: switching gears toward survival and longevity. J Agric Food Chem 56, 9692–8, 2008. doi:10.1021/jf802050h.
67. Mukherjee S, Lekli I, Gurusamy N, Bertelli AA, and Das DK, : Expression of the longevity proteins by both red and white wines and their cardioprotective components, resveratrol, tyrosol, and hydroxytyrosol. Free RadicBiol Med 46, 573–8, 2009. doi:10.1016/j.freeradbiomed.2008.11.005.
68. Bruckbauer A, and Zemel MB, : Synergistic effects of polyphenols and methylxanthines with Leucine on AMPK/Sirtuin-mediated metabolism in muscle cells and adipocytes. PLoS One 2014. doi:10.1371/journal.pone.0089166.
69. Chao HM, Lin DE, Chang Y, Hsu WM, Lee SM, et al.: Ferulic acid, but not tetramethylpyrazine, significantly attenuates retinal ischemia/reperfusion-induced alterations by acting as a hydroxyl radical scavenger. J OculPharmacol Ther 24, 461–72, 2008. doi:10.1089/jop.2008.0005.
70. Chao HM, Chen YH, Liu JH, Hsu WM, Lee SM, et al.: Iron-generated hydroxyl radicals kill retinal cells in vivo: effect of ferulic acid. Hum Exp Toxicol 27, 327–39, 2008. doi:10.1089/jop.2008.0005.
71. Li GL, Wang JJ, Wang JZ, Liu YY, and Jin Y, : Effect of ferulic acid on the proliferation of nerve cells of retinas in vitro. Zhonghua Yan KeZaZhi 39, 650–4, 2003.
72. Jiménez-Flores LM, López-Briones S, Macías-Cervantes MH, Ramírez-Emiliano J, and Pérez-Vázquez V, : A PPARγ, NF-κB and AMPK-dependent mechanism may be involved in the beneficial effects of curcumin in the diabetic db/db mice liver. Molecules 19, 8289–302, 2014. doi:10.3390/molecules19068289.
73. Sun Q, Jia N, Wang W, Jin H, Xu J, et al.: Activation of SIRT1 by curcumin blocks the neurotoxicity of amyloid-β25-35 in rat cortical neurons. BiochemBiophys Res Commun 448, 89–94, 2014. doi:10.1016/j.bbrc.2014.04.066.
74. Liu P, Zou D, Yi L, Chen M, Chen M, et al.: Quercetin ameliorates hypobaric hypoxia-induced memory impairment through mitochondrial and neuron function adaptation via the PGC-1α pathway. Restor Neurol Neurosci 33, 143–57, 2015. doi:10.3233/RNN-140446.
75. Dong J, Zhang X, Zhang L, Bian HX, Xu N, et al.: Quercetin reduces obesity-associated ATM infiltration and inflammation in mice: A mechanism including AMPKα1/SIRT1. J Lipid Res 55, 363–74, 2014. doi:10.1194/jlr.M038786.
76. Suchankova G, Nelson LE, Gerhart-Hines Z, Kelly M, Gauthier MS, et al.: Concurrent regulation of AMP-activated protein kinase and SIRT1 in mammalian cells. BiochemBiophys Res Commun 378, 836–41, 2009. doi:10.1016/j.bbrc.2008.11.130.
77. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, et al.: Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425, 191–196, 2003.
78. Gambini J, Inglés M, Olaso G, Lopez-Grueso R, Bonet-Costa V, et al.: Properties of Resveratrol: In Vitro and In Vivo Studies about Metabolism, Bioavailability, and Biological Effects in Animal Models and Humans. Oxid Med Cell Longev 2015, 837042, 2015. doi:10.1155/2015/837042.
79. Kawashima M, Ozawa Y, Shinmura K, Inaba T, Nakamura S, et al.: Calorie restriction (CR) and CR mimetics for the prevention and treatment of age-related eye disorders. ExpGerontol 48, 1096–100, 2013. doi:10.1016/j.exger.2013.04.002.
80. Kalt W, Hanneken A, Milbury P, and Tremblay F, : Recent research on polyphenolics in vision and eye health. J Agric Food Chem 58, 4001–7, 2010. doi:10.1021/jf903038r.
81. Park D, Jeong H, Lee MN, Koh A, Kwon O, et al.: Resveratrol induces autophagy by directly inhibiting mTOR through ATP competition. Sci Rep 6, 21772, 2016. doi:10.1038/srep21772.
82. Hasima N, and Ozpolat B, : Regulation of autophagy by polyphenolic compounds as a potential therapeutic strategy for cancer. Cell Death Dis 5, 2014. doi:10.1038/cddis.2014.467. Review.
83. Nemec MJ, Kim H, Marciante AB, Barnes RC, Hendrick ED, et al.: Polyphenolics from mango (Mangiferaindica L.) suppress breast cancer ductal carcinoma in situ proliferation through activation of AMPK pathway and suppression of mTOR in athymic nude mice. J NutrBiochem 41, 12–19, 2017. doi:10.1016/j.jnutbio.2016.11.005.
84. Rigacci S, Miceli C, Nediani C, Berti A, Cascella R, et al.: Oleuropeinaglycone induces autophagy via the AMPK/mTORsignalling pathway: A mechanistic insight. Oncotarget 6, 35344–57, 2015. doi:10.18632/oncotarget.6119.
85. Wee LH, Morad NA, Aan GJ, Makpol S, Wan Ngah WZ, et al.: Mechanism of Chemoprevention against Colon Cancer Cells Using Combined Gelam Honey and Ginger Extract via mTOR and Wnt/β-catenin Pathways. Asian Pac J Cancer Prev 16, 6549–56, 2015.
86. Cerella C, Gaigneaux A, Dicato M, and Diederich M, : Antagonistic role of natural compounds in mTOR-mediated metabolic reprogramming. Cancer Lett 356, 251–62, 2015. doi:10.1016/j.canlet.2014.02.008. Review.
87. Adhami VM, Syed DN, Khan N, and Mukhtar H, : Dietary flavonoid fisetin: A novel dual inhibitor of PI3K/Akt and mTOR for prostate cancer management. BiochemPharmacol 84, 1277–81, 2012. doi:10.1016/j.bcp.2012.07.012. Review.
88. Chen X, Dong XS, Gao HY, Jiang YF, Jin YL, et al.: Suppression of HSP27 increases the anti-tumor effects of quercetin in human leukemia U937 cells. Mol Med Rep 13, 689–96, 2016. doi:10.3892/mmr.2015.4600.
89. Hong S, Zhao B, Lombard DB, Fingar DC, and Inoki K, : Cross-talk between sirtuin and mammalian target of rapamycin complex 1 (mTORC1) signaling in the regulation of S6 kinase 1 (S6K1) phosphorylation. J Biol Chem 289, 13132–41, 2014. doi:10.1074/jbc.M113.520734. PMC4036325.
90. Ghosh HS, McBurney M, and Robbins PD, : SIRT1 negatively regulates the mammalian target of rapamycin. PLoS One 5, e9199, 2010. doi:10.1371/journal.pone.0009199. PMC2821410.